{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:15:59Z","timestamp":1791490559941,"version":"4.3.4"},"reference-count":21,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"30","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2019,10,20]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> In National Wilms Tumor Study 5 (NWTS-5), tumor-specific combined loss of heterozygosity of chromosomes 1p and 16q (LOH1p\/16q) was associated with adverse outcomes in patients with favorable histology Wilms tumor. The AREN0533\/AREN0532 studies assessed whether augmenting therapy improved event-free survival (EFS) for these patients. Patients with stage I\/II disease received regimen DD4A (vincristine, dactinomycin and doxorubicin) but no radiation therapy. Patients with stage III\/IV disease received regimen M (vincristine, dactinomycin, and doxorubicin alternating with cyclophosphamide and etoposide) and radiation therapy. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p> Patients were enrolled through the AREN03B2 Biology study between October 2006 and October 2013; all underwent central review of pathology, surgical reports, and imaging. Tumors were evaluated for LOH1p\/16q by microsatellite testing. EFS and overall survival were compared using the log-rank test between NWTS-5 and current studies. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> LOH1p\/16q was detected in 49 of 1,147 evaluable patients with stage I\/II disease (4.27%) enrolled in AREN03B2; 32 enrolled in AREN0532. LOH1p\/16q was detected in 82 of 1,364 evaluable patients with stage III\/IV disease (6.01%) in AREN03B2; 51 enrolled in AREN0533. Median follow-up for 83 eligible patients enrolled in AREN0532\/0533 was 5.73 years (range, 2.84 to 9.63 years). The 4-year EFS for patients with stage I\/II and stage III\/IV disease with LOH1p\/16 was 87.3% (95% CI, 75.1% to 99.5%) and 90.2% (95% CI, 81.8% to 98.6%), respectively. These results are improved compared with the NWTS-5 updated 4-year EFS of 68.8% for patients with stage I\/II disease ( P = .042), and 61.3% for patients with stage III\/IV disease ( P = .001), with trends toward improved 4-year overall survival. The most common grade 3 or higher nonhematologic toxicities with regimen M were febrile neutropenia (39.2%) and infections (21.6%). <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> Augmentation of therapy improved EFS for patients with favorable histology Wilms tumor and LOH1p\/16q compared with the historical NWTS-5 comparison group, with an expected toxicity profile. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.18.01972","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T19:55:21Z","timestamp":1566849321000},"page":"2769-2777","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":75,"title":["Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children\u2019s Oncology Group AREN0532 and AREN0533 Study Report"],"prefix":"10.1200","volume":"37","author":[{"given":"David B.","family":"Dix","sequence":"first","affiliation":[{"name":"British Columbia Children\u2019s Hospital, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad V.","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueh-Yun","family":"Chi","sequence":"additional","affiliation":[{"name":"University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Mullen","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James I.","family":"Geller","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Gratias","sequence":"additional","affiliation":[{"name":"University of Tennessee College of Medicine Chattanooga, Chattanooga, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetika","family":"Khanna","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kalapurakal","sequence":"additional","affiliation":[{"name":"Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Perlman","sequence":"additional","affiliation":[{"name":"Ann and Robert H. Lurie Children\u2019s Hospital, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita L.","family":"Seibel","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Ehrlich","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio","family":"Malogolowkin","sequence":"additional","affiliation":[{"name":"University of California at Davis Comprehensive Cancer Center, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Anderson","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, North Wales, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Gastier-Foster","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital and The Ohio State University College of Medicine, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Shamberger","sequence":"additional","affiliation":[{"name":"Boston Children\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonil","family":"Kim","sequence":"additional","affiliation":[{"name":"University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Grundy","sequence":"additional","affiliation":[{"name":"Stollery Children\u2019s Hospital, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Dome","sequence":"additional","affiliation":[{"name":"Children\u2019s National Medical Center, George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the AREN0532 and AREN0533 study committees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24419"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.1888"},{"key":"B3","first-page":"2331","volume":"54","author":"Grundy PE","year":"1994","journal-title":"Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.651"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/ejso.1999.0742"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.2799"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2014.34.215"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.1931"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7999"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)01322-6"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)00598-4"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26083"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2307\/2344317"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28239"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.0001"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1140"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.05.029"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.100"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1664"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70408-5"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.8.1851"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.18.01972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T08:45:40Z","timestamp":1653813940000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.18.01972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,20]]},"references-count":21,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2019,10,20]]}},"alternative-id":["10.1200\/JCO.18.01972"],"URL":"https:\/\/doi.org\/10.1200\/jco.18.01972","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,20]]},"assertion":[{"value":"2019-07-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}